Market Overview:
The global small molecule tumor drugs market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, rising demand for targeted therapies, and technological advancements in the field of oncology. The small molecule tumor drugs market is segmented by type into tyrosine kinase inhibitors (TKIs), histone deacetylase inhibitors (HDACIs), and target of rapamycin inhibitors (TORIs). The TKI segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing use of TKIs as first-line therapies for various types of cancer and their better efficacy as compared to other drug classes. By application, the small molecule tumor drugs market is segmented into hospitals, clinics, and other applications such as research institutes and contract research organizations (CROs). The hospitals segment accounted for the largest share of this market in 2017 owing to increased use of these drugs for treatment purposes in this setting.
Product Definition:
The term "targeting small molecule tumor drugs" refers to the use of small molecules to specifically target cancer cells. This approach is important because it can minimize damage to healthy cells and tissues, which can occur when traditional chemotherapy agents are used. Additionally, by targeting specific proteins or other molecules that are only found in cancer cells, it may be possible to achieve a more effective treatment with fewer side effects.
Tyrosine Kinase Inhibitor:
Tyrosine kinase inhibitor (TKIs) are a new type of drug that is currently being investigated in clinical trials. The main target of TKIs is the tyrosine kinase enzyme, which has been found to be involved in most non-small cell lung cancer (NSCLC) tumorigenesis and metastasis.
The global Tyrosine Kinase Inhibitor market size was valued at USD 745 million in 2018.
Histone Deacetylase Inhibitor:
Histone deacetylase (HDAC) inhibitors are a new type of pharmaceutical drugs that prevent the action of an enzyme called histone deacetylase. This enzyme is responsible for removing acetyl groups from certain proteins, which results in their destruction. The main function of HDAC inhibitors is to treat cancer by targeting the genetic mutations that develop into tumors.
Application Insights:
The other application segment includes cancer research and development. The growing number of targeted small molecule drug candidates in various stages of clinical trials is expected to drive the market growth over the forecast period. In addition, a rise in prevalence and incidence rates of cancer across the globe is anticipated to further propel demand for these drugs.
Based on application, this market has been segmented into hospital-based clinics and others such asClinical Research Organization (CRO), hospital pharmacies, Oncology Departments at Biopharmaceutical Companies or Hospitals that conduct clinical trials.
Regional Analysis:
North America dominated the global targeting small molecule tumor drugs market with a revenue share of over 40% in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. Moreover, these companies are engaged in extensive R&D activities for the development of novel targeted therapies for cancer treatment. For instance, Pfizer is currently involved in two different phase 3 clinical trials that are evaluating pomalidomide and lenalidomide combination therapy for patients with relapsed/reflexive multiple myeloma (MM). Furthermore, favorable regulatory policies regarding new drug approvals coupled with high healthcare expenditure levels will also help maintain dominance during the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years owing to factors such as increasing target disease population along with rising disposable income levels and improving healthcare infrastructure within this region.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the small molecule tumor drugs market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for small molecule tumor drugs over the forecast period.
- Rising awareness about early diagnosis and treatment: There is an increasing awareness among people about early diagnosis and treatment options for various types of cancers. This has led to an increase in demand for small molecule tumor drugs as they offer better efficacy and fewer side effects as compared to traditional chemotherapy treatments options available currently..
Scope Of The Report
Report Attributes
Report Details
Report Title
Targeting Small Molecule Tumor Drugs Market Research Report
By Type
Tyrosine Kinase Inhibitor, Histone Deacetylase Inhibitor, Target of Rapamycin Inhibitor
By Application
Hospital, Clinic, Other
By Companies
AstraZeneca, Novartis, Bayer, Roche, Pfizer, Beida Pharma, Bristol-Meyer Squibb, Qilu Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
145
Number of Tables & Figures
102
Customization Available
Yes, the report can be customized as per your need.
Global Targeting Small Molecule Tumor Drugs Market Report Segments:
The global Targeting Small Molecule Tumor Drugs market is segmented on the basis of:
Types
Tyrosine Kinase Inhibitor, Histone Deacetylase Inhibitor, Target of Rapamycin Inhibitor
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AstraZeneca
- Novartis
- Bayer
- Roche
- Pfizer
- Beida Pharma
- Bristol-Meyer Squibb
- Qilu Pharma
Highlights of The Targeting Small Molecule Tumor Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tyrosine Kinase Inhibitor
- Histone Deacetylase Inhibitor
- Target of Rapamycin Inhibitor
- By Application:
- Hospital
- Clinic
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Targeting Small Molecule Tumor Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Targeting small molecule tumor drugs is a strategy to improve the efficacy and safety of cancer treatments. These drugs are designed to interact with specific proteins or molecules in the cancer cells, disrupting their function and causing them to die.
Some of the key players operating in the targeting small molecule tumor drugs market are AstraZeneca, Novartis, Bayer, Roche, Pfizer, Beida Pharma, Bristol-Meyer Squibb, Qilu Pharma.
The targeting small molecule tumor drugs market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Targeting Small Molecule Tumor Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Targeting Small Molecule Tumor Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Targeting Small Molecule Tumor Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Targeting Small Molecule Tumor Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Targeting Small Molecule Tumor Drugs Market Size & Forecast, 2018-2028
4.5.1 Targeting Small Molecule Tumor Drugs Market Size and Y-o-Y Growth
4.5.2 Targeting Small Molecule Tumor Drugs Market Absolute $ Opportunity
Chapter 5 Global Targeting Small Molecule Tumor Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
5.2.1 Tyrosine Kinase Inhibitor
5.2.2 Histone Deacetylase Inhibitor
5.2.3 Target of Rapamycin Inhibitor
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Targeting Small Molecule Tumor Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Targeting Small Molecule Tumor Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Targeting Small Molecule Tumor Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Targeting Small Molecule Tumor Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Targeting Small Molecule Tumor Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
9.6.1 Tyrosine Kinase Inhibitor
9.6.2 Histone Deacetylase Inhibitor
9.6.3 Target of Rapamycin Inhibitor
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Targeting Small Molecule Tumor Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Targeting Small Molecule Tumor Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
10.6.1 Tyrosine Kinase Inhibitor
10.6.2 Histone Deacetylase Inhibitor
10.6.3 Target of Rapamycin Inhibitor
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Targeting Small Molecule Tumor Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Targeting Small Molecule Tumor Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
11.6.1 Tyrosine Kinase Inhibitor
11.6.2 Histone Deacetylase Inhibitor
11.6.3 Target of Rapamycin Inhibitor
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Targeting Small Molecule Tumor Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Targeting Small Molecule Tumor Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
12.6.1 Tyrosine Kinase Inhibitor
12.6.2 Histone Deacetylase Inhibitor
12.6.3 Target of Rapamycin Inhibitor
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Targeting Small Molecule Tumor Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Targeting Small Molecule Tumor Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Targeting Small Molecule Tumor Drugs Market Size Forecast by Type
13.6.1 Tyrosine Kinase Inhibitor
13.6.2 Histone Deacetylase Inhibitor
13.6.3 Target of Rapamycin Inhibitor
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Targeting Small Molecule Tumor Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Targeting Small Molecule Tumor Drugs Market: Competitive Dashboard
14.2 Global Targeting Small Molecule Tumor Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AstraZeneca
14.3.2 Novartis
14.3.3 Bayer
14.3.4 Roche
14.3.5 Pfizer
14.3.6 Beida Pharma
14.3.7 Bristol-Meyer Squibb
14.3.8 Qilu Pharma
